https://orcid.org/0000-0002-2550-5027
References
- Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-Host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):449–455.
- Bachier CR, Aggarwal SK, Hennegan K, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transplant Cell Ther. 2021;27(6):504.e1–e6.
- Goerner M, Gooley T, Flowers ME, et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant. 2002;8(1):47–56.
- Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
- Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(12):1380–1384.
- Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-Host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.
- Jones C, Fernandez L, Weimersheimer P, et al. Estimating the burden of cost in chronic graft-versus-host disease: a human Capital approach. J Health Econ Outcome Res. 2016;4(2)06/01:113–118.
- Saad A, de Lima M, Anand S, et al. Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(5):599–634.
- Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021;138(22):2278–2289.
- Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic Graft-Versus-Host disease. J Clin Oncol. 2021;39(17):1888–1898.
- Bureau USC. Data from: American Community Survey Demographic and Housing Estimates. 2018.
- 2019 U.S. Population Estimates Continue to Show the Nation’s Growth Is Slowing. 2019. https://www.census.gov/newsroom/press-releases/2019/popest-nation.html.
- (CIBMTR) CfIBMTR. 2019 Annual Report. 2019. https://www.cibmtr.org/About/AdminReports/Documents/2019CIBMTRAnnualReport.pdf.
- National Marrow Donor Program acftCWBYCTPottUSDoHaHS, Health Resources and Services Administration, Healthcare Systems Bureau. Transplant Activity Report. 2019. https://bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics/transplant-activity-report.
- Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
- Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using national institutes of health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207–1215.
- Rezurock Highlights of Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf.
- Data from: RED BOOK Online. IBM Micromedex [database online]. 2021.
- Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–238.
- Jakafi Highlights of Prescribing Information. 2021. https://www.jakafi.com/pdf/prescribing-information.pdf.
- Imbruvica Highlights of Prescribing Information. 2020. https://www.imbruvica.com/files/prescribing-information.pdf.
- Report to the Congress: Medicare Payment Policy, March 2020. 2020.
- An Analysis of Private-Sector Prices for Hospital Admissions. 2017.
- (CMS) CfMMS. Data from: Inpatient Charge Data FY 2017. 2017. Deposited November 27. 2019.
- Bachier C, Eiznhamer D, Milgroom A, et al. Costs and adverse events associated with ibrutinib or ruxolitinib in chronic Graft-Versus-Host disease. Blood. 2020;136(Supplement 1):14–15.
- Abedin S, McKenna E, Chhabra S, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1689–1694.
- Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250.